ESC 365 - Complication comparison in intermediate-to-high risk venous thromboembolism patients, treated with high vs standard dose apixaban and rivaroxaban after low molecular weight heparin

ESC Premium Access

Complication comparison in intermediate-to-high risk venous thromboembolism patients, treated with high vs standard dose apixaban and rivaroxaban after low molecular weight heparin

Session: Pearls of acute pulmonary embolism

Topic: Venous Thromboembolism

Speaker: Doctor A. Garner (Slagelse, DK)

Event: ESC Congress 2024

Congress Presentation

About the speaker

Doctor Anton Kristoffer Garner

Slagelse Hospital, Slagelse (Denmark)

0 follower

7 more presentations in this session

Epidemiology of acute pulmonary embolism in children and adolescents from nationwide US hospital data, 2016 and 2019

Speaker: Mr S. Wolf (Zurich, CH)

A simple and reliable computed tomographic measure for the evaluation of right ventricle remodelling in acute PE: right ventricle apical angle

Speaker: Doctor B. Kultursay (Istanbul, TR)

A novel dynamic risk score to predict venous thromboembolism (VTE) recurrences after 3 months of anticoagulation in patients with incident VTE and without active cancer.

Speaker: Doctor A. Cohen (London, GB)

Efficacy and safety of long-term edoxaban treatment for low body weight cancer patients with isolated distal deep vein thrombosis: a post-hoc subgroup analysis of the ONCO DVT study

Speaker: Doctor T. Nagai (Kyoto, JP)

Baseline characteristics, management patterns and outcome in patients with pulmonary embolism and malignancy: Insights from a single-centre study

Speaker: Doctor H. Tokgoz (Istanbul, TR)

Access the full session

Pearls of acute pulmonary embolism

Speakers: Doctor A. Garner, Mr S. Wolf, Doctor B. Kultursay, Doctor A. Cohen, Doctor T. Nagai...

About the event

ESC Congress 2024

30 August - 2 September 2024

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources